注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Tango Therapeutics Inc是一家精準腫瘤學公司,致力於發現和開發針對未滿足醫療需求的患者的腫瘤抑制基因丟失的藥物。該公司的候選產品包括TNG908和泛素特異性蛋白酶1(USP1)。TNG908是一種合成的致死小分子蛋白精氨酸甲基轉移酶5(PRMT5)抑製劑,旨在選擇性地在甲基硫腺苷磷酸化酶(MTAP)缺失的癌細胞中發揮作用。MTAP缺失發生在所有人類腫瘤中,包括非小細胞肺癌(NSCLC)、間皮瘤、胰腺癌、膽管癌和膠質母細胞瘤。該公司專注於啟動I/II期臨床試驗。USP1是BRCA1突變乳腺癌的合成致命靶點發現篩選。該公司的先導分子在BRCA2突變患者衍生的異種移植物中也具有活性,包括對聚合酶(PARP)抑制具有內在抗性的BRCA1和BRCA2突變模型。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Carole L. Nuechterlein | 59 | 2020 | Independent Director |
Aaron I. Davis | 43 | 2020 | Chairman & CEO |
James G. Christensen | 53 | 2020 | Independent Director |
Charles M. Baum | 63 | 2020 | Independent Director |
Christopher Fuglesang | 52 | 2020 | President & Director |
Richard A. Heyman | 64 | - | Independent Director |
James B. Avery | 58 | 2020 | Independent Director |
Barbara L. Weber | 66 | 2017 | President, CEO & Director |
Alexis A. Borisy | 51 | 2017 | Independent Chairman |
Malte Peters | 61 | 2018 | Independent Director |
John G. Doench | - | 2021 | Member of Scientific Advisory Board |
Mace L. Rothenberg | 66 | 2021 | Independent Director |
Lesley Ann Calhoun | 57 | 2021 | Independent Director |
Ulrich Elling | - | 2021 | Member of Scientific Advisory Board |
John Ketchum | - | 2023 | Independent Director |
Kanishka Ram Pothula | 39 | 2023 | Independent Director |
Antoni Ribas | 57 | 2021 | Founder & Member of Scientific Advisory Board |
Alan Ashworth | 63 | 2021 | Founder & Member of Scientific Advisory Board |
William G. Kaelin | 66 | 2021 | Founder & Member of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核